Completed
A Phase 1, Single Dose Study of JZP-386 to Evaluate Safety, Pharmacokinetics and Pharmacodynamics
NCT02215499
- Conditions
- Disorders of Excessive Somnolence, Dyssomnias, Mental Disorders, +5 more
- Locations
-
- Quotient Clinical Ltd. Ruddington, Nottingham, United Kingdom